Researchers have identified a potential treatment pathway for Verheij syndrome, a rare genetic condition characterized by developmental delays and short stature. The discovery centers on the role of vitamin B12 in correcting metabolic disruptions caused by faulty RNA splicing.
The findings emerged from experiments using C. elegans, a microscopic roundworm widely used in biological research. Scientists initially sought genes influencing lifespan but instead focused on a mutation in a gene responsible for RNA splicing. This specific gene is also linked to Verheij syndrome in humans.
Metabolic Disruption in Worm Models
Worms carrying the mutation exhibited growth problems that mirrored key features of the human disorder. Their development slowed significantly, and they remained smaller than normal. To understand the cause, researchers analyzed the worms’ metabolism and genetic makeup.
The mutation disrupted metabolic pathways that rely on vitamin B12. These pathways are essential for healthy growth and normal cellular activity. When the process failed, the worms suffered from developmental abnormalities.
Jonathan Klschbach, the study’s first author, noted the unexpected connection. “We were surprised to find that a change in a fundamental process of RNA processing had such a targeted effect on vitamin B12-dependent metabolism,” Klschbach said. “Even more exciting was that we were able to largely correct the consequences of this change in the worm model using vitamin B12.”
When researchers administered additional vitamin B12 to the affected worms, the treatment restored normal metabolic processes. The supplementation also corrected the developmental issues associated with the genetic mutation.
Human Cell Analysis and Future Steps
To determine if these results could apply to humans, the team examined publicly available datasets from human cells. They also collaborated with Hormos Dafsari, a neuropediatrician at the University Hospital Cologne, to collect blood samples from patients diagnosed with Verheij syndrome.
The analysis revealed evidence of similar metabolic changes in humans. This suggests that the vitamin B12-related pathways affected in the worms likely play a role in the human disorder as well.
Adam Antebi, director at the Max Planck Institute for Biology of Ageing and lead author of the study, emphasized the value of basic research. “Our study is a good example of how basic research on model organisms can provide new insights into human diseases,” Antebi said. “A fundamental biological question can thus give rise to a new approach that could also become medically relevant in the long term.”
While the results are promising, researchers have not yet confirmed whether vitamin B12 supplementation improves symptoms in people with Verheij syndrome. Additional studies are required to determine if the benefits observed in worms can be translated into a clinical treatment for patients.
The discovery also suggests that metabolic disruptions may contribute more significantly to diseases caused by faulty RNA splicing than previously recognized. Understanding these connections could help researchers identify new therapeutic strategies for other rare genetic conditions.
Source: ScienceDaily

